HomeCompareHOLX vs ARES

HOLX vs ARES: Dividend Comparison 2026

HOLX yields 2.65% · ARES yields 4.37%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARES wins by $2929.61M in total portfolio value
10 years
HOLX
HOLX
● Live price
2.65%
Share price
$75.55
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.6K
Annual income
$314.03
Full HOLX calculator →
ARES
ARES
● Live price
4.37%
Share price
$107.66
Annual div
$4.71
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2929.64M
Annual income
$2,806,406,662.94
Full ARES calculator →

Portfolio growth — HOLX vs ARES

📍 ARES pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHOLXARES
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HOLX + ARES cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HOLX pays
ARES pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HOLX
Annual income on $10K today (after 15% tax)
$225.02/yr
After 10yr DRIP, annual income (after tax)
$266.93/yr
ARES
Annual income on $10K today (after 15% tax)
$371.87/yr
After 10yr DRIP, annual income (after tax)
$2,385,445,663.50/yr
At 15% tax rate, ARES beats the other by $2,385,445,396.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HOLX + ARES for your $10,000?

HOLX: 50%ARES: 50%
100% ARES50/50100% HOLX
Portfolio after 10yr
$1464.83M
Annual income
$1,403,203,488.48/yr
Blended yield
95.79%
📊

Analyst Conviction Gap

Where Wall Street is split right now

HOLX
Analyst Ratings
18
Buy
23
Hold
1
Sell
Consensus: Hold
Price Target
$77.80
+3.0% upside vs current
Range: $76.00 — $79.00
Altman Z
4.2
Piotroski
7/9
ARES
Analyst Ratings
1
Strong
15
Buy
5
Hold
Consensus: Buy
Price Target
$179.25
+66.5% upside vs current
Range: $148.00 — $215.00
Altman Z
1.5
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HOLX buys
0
ARES buys
0
No recent congressional trades found for HOLX or ARES in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHOLXARES
Forward yield2.65%4.37%
Annual dividend / share$2.00$4.71
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%100%
Portfolio after 10y$23.6K$2929.64M
Annual income after 10y$314.03$2,806,406,662.94
Total dividends collected$2.9K$2920.90M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldBuy
Analyst price target$77.80$179.25

Year-by-year: HOLX vs ARES ($10,000, DRIP)

YearHOLX PortfolioHOLX Income/yrARES PortfolioARES Income/yrGap
1← crossover$10,965$264.73$11,575$874.98$610.00ARES
2$12,004$271.27$14,278$1,893.05$2.3KARES
3$13,121$277.55$19,643$4,364.80$6.5KARES
4$14,323$283.54$32,241$11,223.63$17.9KARES
5$15,615$289.27$68,932$34,434.38$53.3KARES
6$17,003$294.73$211,368$137,610.38$194.4KARES
7$18,493$299.93$1,014,866$788,702.55$996.4KARES
8$20,093$304.87$8,164,206$7,078,299.39$8.14MARES
9$21,809$309.57$115,169,668$106,433,966.79$115.15MARES
10$23,649$314.03$2,929,638,207$2,806,406,662.94$2929.61MARES

HOLX vs ARES: Complete Analysis 2026

HOLXHealthcare

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Full HOLX Calculator →

ARESStock

Ares Management Corporation operates as an alternative asset manager in the United States, Europe, and Asia. The company's Tradable Credit Group segment manages various types of investment funds, such as commingled and separately managed accounts for institutional investors, and publicly traded vehicles and sub-advised funds for retail investors in the tradable and non-investment grade corporate credit markets. Its Direct Lending Group segment provides financing solutions to small-to-medium sized companies. The company's Private Equity Group segment focuses on majority or shared-control investments primarily in under-capitalized companies. Its Real Estate Group segment invests in new developments and the repositioning of assets, with a focus on control or majority-control investments; and originates and invests in a range of self-originated financing opportunities for middle-market owners and operators of commercial real estate. The firm was previously known as Ares Management, L.P. Ares Management Corporation was founded in 1997 and is headquartered in Los Angeles, California with additional offices in the United States, Europe and Asia. Ares Management GP LLC is the general partner of the company.

Full ARES Calculator →
📬

Get this HOLX vs ARES comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HOLX vs SCHDHOLX vs JEPIHOLX vs OHOLX vs KOHOLX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.